Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.66 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.66 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27225148 | 0.90 | DDB1 (0.66) | DDB1CRBNBACE1 | |
| SCHEMBL31444146 | 0.90 | DDB1 (0.66) | DDB1CRBNBACE1 | |
| SCHEMBL29197146 | 0.89 | DDB1 (0.64) | DDB1CRBNBACE1 | |
| SCHEMBL30955788 | 0.88 | DDB1 (0.63) | DDB1CRBNBACE1 | |
| SCHEMBL31444160 | 0.87 | DDB1 (0.61) | DDB1CRBNBACE1 | |
| SCHEMBL31444018 | 0.86 | DDB1 (0.58) | DDB1CRBNBACE1 | |
| SCHEMBL23301226 | 0.85 | DDB1 (0.67) | DDB1CRBN | |
| SCHEMBL21876964 | 0.85 | DDB1 (0.67) | DDB1CRBN | |
| SCHEMBL21876868 | 0.84 | DDB1 (0.63) | DDB1CRBNBACE1 | |
| SCHEMBL29179837 | 0.82 | DDB1 (0.69) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | DDB1 206/4885CRBN 302/4885BACE1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.